News

Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B
Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.
Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration
Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...
MedCity News2d
Merck Breathes Life Into Its Respiratory Prospects With $10B Deal to ...
Merck has reached a $10 billion deal to acquire Verona Pharma, a biotech whose first-in-class drug is already commercialized in one prevalent lung disorder and is showing promise in other ...
Merck shells out $10 billion for London-based lung therapy firm Verona
Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's ...
Verona Pharma Shares Pop Premarket on Report of Merck Takeover
Verona Pharma shares jumped in premarket trading Wednesday after the Financial Times reported that Merck & Co. is nearing a $10 billion deal to buy the U.K. drugmaker.